TY  - JOUR
A1  - Podda, Maurizio
A1  - Kovács, Maximilian
A1  - Hellmich, Martin
A1  - Roth, Rebecca
A1  - Marouan, Zarrouk
A1  - Kraus, Daria Christina
A1  - Prinz-Langenohl, Reinhild
A1  - Cornely, Oliver Andreas
T1  - A randomised controlled multicentre investigator-blinded clinical trial comparing efficacy and safety of surgery versus complex physical decongestive therapy for lipedema (LIPLEG)
T2  - Trials
N2  - Background: Lipedema is a chronic disorder of the adipose tissue that affects mainly women, characterised by symmetrical, excessive fatty tissue on the legs and pain. Standard conservative treatment is long-term comprehensive decongestive therapy (CDT) to alleviate lipedema-related pain and to improve psychosocial well-being, mobility and physical activity. Patients may benefit from surgical removal of abnormally propagated adipose tissue by liposuction. The LIPLEG trial evaluates the efficacy and safety of liposuction compared to standard CDT.
Methods/design: LIPLEG is a randomised controlled multicentre investigator-blinded trial. Women with lipedema (n=405) without previous liposuction will be allocated 2:1 to liposuction or CDT. The primary outcome of the trial is leg pain reduction by ≥2 points on a visual analogue scale ranging 0–10 at 12 months on CDT or post-completion of liposuction. Secondary outcomes include changes in leg pain severity, health-related quality of life, depression tendency, haematoma tendency, prevalence of oedema, modification physical therapy scope, body fat percentage, leg circumference and movement restriction.
The primary analysis bases on intention-to-treat. Success proportions are compared using the Mantel-Haenszel test stratified by lipedema stage at a 5% two-sided significance level. If this test is statistically significant, the equality of the response proportions in the separate strata is evaluated by Fisher’s exact test in a hierarchical test strategy.
Discussion: LIPLEG assesses whether surgical treatment of lipedema is safe and effective to reduce pain and other lipedema-related health issues. The findings of this trial have the potential to change the standard of care in lipedema.
Trial registration: ClinicalTrials.gov NCT04272827. Registered on February 14, 2020.
Trial status: Protocol version is 02_0, December 17, 2019
KW  - Lipedema
KW  - Complex decongestive therapy
KW  - Liposuction
KW  - Randomisation
KW  - Phase 3
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/69636
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-696365
SN  - 1468-6694
SN  - 1745-6215
N1  - The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
N1  - The clinical trial is publicly funded by the ‘Gemeinsamer Bundesausschuss’ (G-BA, Federal Joint Committee). The Federal Joint Committee is the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany. Open Access funding enabled and organized by Projekt DEAL.
VL  - 22
IS  - art. 758
SP  - 1
EP  - 11
PB  - BioMed Central
CY  - London
ER  -